Integrating Molecular Testing into Decision Making in NSCLC : Episode 4

Video

October 19, 2022

Average Turnaround Time for NSCLC Molecular Testing

Author(s):

Dr Neil Morganstein explains the typical turnaround times for molecular testing he sees and the challenges that prolong the process.

EP: 1.Challenges With and Strategies for Tissue Procurement in NSCLC

EP: 2.Enhancing Communication Among the Multidisciplinary Care Team

EP: 3.Best Practices for Accurate Tissue Genotyping in NSCLC

Now Viewing

EP: 4.Average Turnaround Time for NSCLC Molecular Testing

EP: 5.Types of Tissue Next-Generation Sequencing Platforms in NSCLC

EP: 6.Using Liquid Biopsy for Molecular Testing in NSCLC

EP: 7.Integrating Molecular Testing Results into Electronic Medical Records

EP: 8.Receiving Molecular Testing Results for NSCLC

EP: 9.Financial Considerations with Molecular Testing for Patients With NSCLC

EP: 10.The Future of Molecular Testing in NSCLC

Related Content

OncLive's OncFive: The Top 5 Oncology Articles of the Week

December 21st 2024

The OncFive: Top Oncology Articles for the Week of 12/15

December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

December 20th 2024

China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC

October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

December 18th 2024

FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC

December 17th 2024

FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC